SNOA vs. HCWB, FLGC, SNSE, IMNN, BGXX, AIM, HOTH, CRVO, WENA, and RLMD
Should you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include HCW Biologics (HCWB), Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), CervoMed (CRVO), ANEW Medical (WENA), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.
Sonoma Pharmaceuticals vs.
Sonoma Pharmaceuticals (NASDAQ:SNOA) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Sonoma Pharmaceuticals received 210 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 67.50% of users gave Sonoma Pharmaceuticals an outperform vote.
Sonoma Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
Sonoma Pharmaceuticals has a net margin of -27.21% compared to HCW Biologics' net margin of -1,067.82%. Sonoma Pharmaceuticals' return on equity of -59.58% beat HCW Biologics' return on equity.
Sonoma Pharmaceuticals has higher revenue and earnings than HCW Biologics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 49.9% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, HCW Biologics had 2 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for HCW Biologics and 0 mentions for Sonoma Pharmaceuticals. HCW Biologics' average media sentiment score of 0.44 beat Sonoma Pharmaceuticals' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.
Summary
HCW Biologics beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Sonoma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonoma Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SNOA) was last updated on 1/22/2025 by MarketBeat.com Staff
